Document is current
Any future updates will be listed below
-
Authors
Ghanem, Paola
Marrone, Kristen
Shanbhag, Satish
Brahmer, Julie R.
Naik, Rakhi P. https://orcid.org/0000-0001-5562-1283
- License Information
-
More Information
Article History
Received: 21 August 2021
Accepted: 27 September 2021
First Online: 28 December 2021
Declarations
:
: Not applicable.
: Not applicable.
: Not applicable.
: Paola Ghanem has no financial or non-financial interests to disclose. Satish Shanbhag has received consulting fees from Takeda oncology, GSK, Daiichi-Sankyo, Kura oncology, Celgene, Beigene, and institutional research grant support from Daiichi Sankyo. Kristen Marrone consulted and was part of the advisory boards for AstraZeneca and Amgen. Julie R. Brahmer is a consultant for Merck, Bristol Myers Squibb, Genentech/Roche, Amgen, GlaxoSmithKline, AstraZeneca, Eli Lilly, Sanofi, and Regeneron. Julie R. Brahmer has received grant funding from AstraZeneca and Bristol Myers Squib. Rakhi P. Naik has received funding from Rigel pharmaceuticals. All disclosures are unrelated to the subject matter of this manuscript. The authors did not receive support from any organization for the submitted work.
